Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader
Open Access
- 20 March 2026
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 40 (6) , 1314-1317
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (CA233332)
- Michael W. and Georgia Taylor Michelson
- National Cancer Institute (R01CA251801)
This publication has 14 references indexed in Scilit:
- Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemiaBlood Neoplasia, 2024
- Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancersScience, 2024
- Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127Science, 2024
- B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cellsBlood Cancer Journal, 2022
- Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain MalignanciesBlood, 2021
- Chronic lymphocytic leukaemia: from genetics to treatmentNature Reviews Clinical Oncology, 2019
- Targeting B cell receptor signalling in cancer: preclinical and clinical advancesNature Reviews Cancer, 2018
- Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemiaNature Genetics, 2011
- Platelet-derived growth factor (PDGF)–PDGF receptor interaction activates bone marrow–derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switchBlood, 2010
- International network of cancer genome projectsNature, 2010